Boulevard Bio ended stealth with about $65 million in launch financing from Deerfield Management to build an antibody pipeline focused on B cell-driven autoimmune disease. The company is advancing three multi-specific antibody programs and is initially evaluating BLVD101, a bispecific targeting BAFF and APRIL, in IgA nephropathy. Boulevard said early Phase 1 interim data from healthy volunteers support a potential quarterly dosing interval, with treatment every 12 weeks described as a key differentiator versus more frequent schedules. If sustained in later trials, that could translate into a significant quality-of-life advantage for chronic autoimmune patients. Backed entirely by Deerfield’s internal discovery and development engine (3DC), Boulevard’s structure is built around internal target validation and fast movement into early clinical testing. The company’s approach reflects continued investor focus on dosing convenience as well as modality differentiation within antibody therapeutics.